Fresh from its acquisition of Juno Therapeutics, Celgene has announced that its Executive Chairman Bob Hurgin is to retire effective 5 February, while Chief Executive Officer Mark Alles will step up to assume the additional role of Chairman of the Board of Directors.
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.